Cipla launches generic remdesivir at Rs 4k per vial

Cipla has launched the generic version of COVID-19 treatment drug remdesivir, called Cipremi,  at a price which is among the lowest globally – ₹4,000 per 100 mg vial. Inspired by its overall philosophy of driving access and affordability, the drug will be available through government and hospital channels only to ensure equitable distribution.

“We are proud to commercially launch Cipremi today; amongst the lowest priced globally, and aim to supply over 80,000 vials within the first month itself,” Cipla Executive VP and CEO (India Business) Nikhil Chopra stated. “Cipla will also be donating some amount of the drug as part of its efforts to support the community in this time of need,” he added.

Cipremi has got the approval of Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need. Some of the other players manufacturing indigenous versions of remdesivir include Mylan NV & Hetero. While the former’s drug will be priced at Rs 4,800 per 100 mg vial; the latter as fixed a maximum retail price of Rs 5,400 per vial for the drug.